EXPERIENCE
The DAXXIFY^® Difference

The first and only neurotoxin formulated with a novel, custom-engineered peptide.^1,6-10

Offers sustained symptom control and the potential for MORE GOOD DAYS to your cervical dystonia patients.¹¹

LEARN MORE ABOUT DAXXIFY®

Side portrait close up of a woman's neck

DAXXIFY^® demonstrates long-lasting relief to help control symptom re-emergence.^11*

Per the Phase 3 pivotal trial, DAXXIFY^® is generally safe and well tolerated, with no serious treatment-related adverse events reported.^1,2

Learn more about DAXXIFY^®
performance in the pivotal trial.

*Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with DAXXIFY® 250U. In patients that requested retreatment prior to the loss of > 80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.^2-3

DAXXIFY^® is the only botulinum toxin formulated with a novel, custom-engineered peptide.^1,6-10

Proprietary peptide 3D image

Learn more about the unique DAXXIFY^® formulation from:

Conor Gallagher, PhD

VP, Medical Affairs and Scientific Innovation

The ASPEN program

DAXXIFY^® demonstrated impressive performance in the ASPEN-1 pivotal study and the ASPEN open-label study (OLS).^2,3

View resources below.

Additional Clinical Information

Access DAXXIFY™

Resources to support physicians, practices and patients

Our Revance Reimbursement and Access team is dedicated to providing solutions tailored to your practice’s specific needs.

• Benefits investigation, prior authorization and appeal support
• Navigating payer policies and requirements
• Billing and coding education
• Patient affordability programs

Access DAXXIFY™ resources Access DAXXIFY™, Revance Reimbursement and Access Managers and the information contained in this website is intended for informational purposes only and does not represent legal or billing advice. It is the responsibility of the provider and practice to ensure the accuracy of all information and claims that are submitted for reimbursement.

EXPERIENCEThe DAXXIFY® Difference

DAXXIFY® demonstrates long-lasting relief to help control symptom re-emergence.11*

Per the Phase 3 pivotal trial, DAXXIFY® is generally safe and well tolerated, with no serious treatment-related adverse events reported.1,2

DAXXIFY® is the only botulinum toxin formulated with a novel, custom-engineered peptide.1,6-10

Learn more about the unique DAXXIFY® formulation from: